Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

By D. Reardon, A. Brandes, A. Omuro, P. Mulholland, M. Lim, A. Wick, J. Baehring, M. Ahluwalia, P. Roth, O. Bähr and 10 more. JAMA Oncology, 2020

1,220 citations recorded by the source corpus.

Key Points Question Does programmed cell death 1 immune checkpoint inhibition with nivolumab improve overall survival compared with bevacizumab treatment for patients with recurrent glioblastoma? Findings In this randomized phase 3 clinical trial of 369 patients diagnosed with recurrent glioblastoma treated with nivolumab, an improved survival benefit was not observed in patients who received nivolumab compared with bevacizumab-treated control patients. Meaning Additional research is needed; nivolumab monotherapy did not improve overall survival compared with bevacizumab in the treatment of recurrent glioblastoma. A study of nivolumab in combination with radiotherapy and temozolomide in patients with newly diagnosed glioblastoma with methylated MGMT promoter is ongoing.

Subfields: Genetics, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/44d506dd68903c5b53c344b1c3f03162f5f609e8